Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) Insider Sells $72,336.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 1,507 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $72,336.00. Following the transaction, the insider now directly owns 91,163 shares in the company, valued at $4,375,824. The trade was a 1.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Dennis Cho also recently made the following trade(s):

• On Monday, November 4th, Dennis Cho sold 659 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total value of $27,388.04.
• On Wednesday, October 2nd, Dennis Cho sold 3,104 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total value of $134,123.84.
• On Friday, September 20th, Dennis Cho sold 234 shares of Twist Bioscience stock. The shares were sold at an average price of $46.94, for a total transaction of $10,983.96.

Twist Bioscience Price Performance

NASDAQ TWST opened at $36.89 on Friday. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -9.66 and a beta of 1.78. Twist Bioscience Co. has a 12 month low of $18.80 and a 12 month high of $60.90. The company’s fifty day moving average price is $43.90 and its two-hundred day moving average price is $45.91.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Leerink Partners boosted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Barclays dropped their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Evercore ISI lifted their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Robert W. Baird upped their price target on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Finally, JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.22.

Hedge Funds Weigh In On Twist Bioscience

Several large investors have recently modified their holdings of the stock. Signaturefd LLC raised its position in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares in the last quarter. EdgeRock Capital LLC acquired a new position in shares of Twist Bioscience in the 2nd quarter valued at about $43,000. Blue Trust Inc. lifted its holdings in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after acquiring an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new position in Twist Bioscience in the second quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after purchasing an additional 381 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.